Clinical Trial: CP-481,715 Nickel Allergy Study.
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Placebo-Controlled, Randomized, Parallel Group, Multiple-Dose Study to Evaluate the Effects of CP-481,715 on Clinical Response and Cellular Infiltration Following Contact Allergen Challenge to the Ski
Brief Summary: To evaluate the suitability of contact allergy as a method for the evaluation of c-chemokine receptor-1 antagonist.
Detailed Summary:
Sponsor: Pfizer
Current Primary Outcome: Effect of CP-481,715 on clinical response and cell infiltration after nickel challenge
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Pfizer
Dates:
Date Received: August 30, 2005
Date Started: September 2003
Date Completion: October 2005
Last Updated: July 23, 2006
Last Verified: November 2005